These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
23. Improvement in the regulation of cellular cholesterologenesis in diabetes: the effect of reduction in serum cholesterol by simvastatin. Owens D; Stinson J; Collins P; Johnson A; Tomkin GH Diabet Med; 1991; 8(2):151-6. PubMed ID: 1827401 [TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
26. Reductase inhibitor therapy of hypercholesterolemia. Kreisberg RA Trans Am Clin Climatol Assoc; 1991; 102():153-63; discussion 163-5. PubMed ID: 2130558 [No Abstract] [Full Text] [Related]
27. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637 [TBL] [Abstract][Full Text] [Related]
28. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL; McTavish D Drugs; 1995 Aug; 50(2):334-63. PubMed ID: 8521762 [TBL] [Abstract][Full Text] [Related]